ClinicalTrials.gg
CompletedNCT04655313Updated Dec 15, 2023Results posted

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

A Phase 2 interventional study of ARQ-151 cream 0.3% in Psoriasis and Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 17 sites in 3 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.

Enrollment
13th of 17
20 · median 46
Started
2020
with 2 others
Phase 2
7 of 17
1 open now
Registered
10th of 17
by date
Lead sponsor
9 of 17
Arcutis Biotherapeutics, Inc.

Among the 17 studies testing roflumilast in Psoriasis, this one is the 13th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing roflumilast in Psoriasis, or all of them as a file.
02

Study summary

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:

03

Conditions studied

  • Psoriasis
  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of parent(s) or legal guardian, and, if age appropriate, assent by the subject, as required by local laws.
  • Males or females, 6 to 11 years old (inclusive).
  • Clinical diagnosis of psoriasis vulgaris of at least 2 months duration as determined by the Investigator or through subject interview. Stable disease for the past 3 weeks.
  • Psoriasis vulgaris on the face, extremities, trunk, and/or intertriginous areas involving at least 2% of BSA (excluding the scalp, palms, and soles).
  • An Investigator Global Assessment of disease severity (IGA) of at least Mild ('2') at Baseline.
  • Subject has adequate venous access for PK sampling in areas not involved by plaque psoriasis and not being treated with ARQ-151 (e.g., back of the hands).
  • Females of (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective throughout the duration of the trial and for one week after application of the last dose.
  • Females of non-childbearing potential must be pre-menarchal.
  • In good health as judged by the Investigator, based on medical history, physical examination, 12-lead (ECG), serum chemistry labs, hematology values, and urinalysis.
  • Subjects and parent(s)/legal guardian(s) are considered reliable and capable of adhering to the Protocol and Visit Schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any serious medical or psychiatric condition or laboratory, , vital signs, or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
  • Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris
  • Current diagnosis of non-plaque form of psoriasis (e.g., guttate, erythrodermic/exfoliative, palmoplantar only involvement, or pustular psoriasis). Current diagnosis of drug-induced psoriasis.
  • Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
  • Subjects who cannot discontinue the use of strong cytochrome P-450 inducers for 2 weeks prior to Baseline/Day 1and during the study period.
  • Subjects who cannot discontinue the use of strong cytochrome P-450 CYP3A4 inhibitors for 2 weeks prior to Baseline/Day 1 and during the study period.
  • Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.
  • Subjects who cannot discontinue specific systemic therapies and/or topical therapies prior to the Baseline/Day 1 and during the study period according to the protocol.
  • Subjects with any infection requiring oral or intravenous administration of antibiotics, antifungal or antiviral agents within 2 weeks prior to Baseline/Day 1.
  • Subjects with a CDI-2 (parent report) raw score >20 at Screening/Baseline
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    ARQ-151 cream 0.3%

    Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks

    Drug: ARQ-151 cream 0.3%

Interventions

  • ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks

    Also known as: Topical roflumilast

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of ARQ-151 Cream 0.3%

    Plasma levels of circulating roflumilast were determined at 2 points in the study.

    Time frame: Predose on Days 14 and 28

  2. Plasma Concentration of the Roflumilast Major N-oxide Metabolite

    Plasma levels of circulating the roflumilast major N-oxide metabolite were determined at 2 points in the study.

    Time frame: Predose on Days 14 and 28

  3. Number of Participants With ≥1 Adverse Event (AE)

    The number of participants with adverse events during the treatment period is reported. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.

    Time frame: Up to 28 days

  4. Number of Participants With Application Site Reactions

    The number of subjects experiencing an application site skin reactions by investigator assessment is reported. The investigator assessed for erythema prior to that day's application of investigational product.

    Time frame: Baseline (Day 1), Day 7, and Day 14

07

Results

Posted Dec 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneARQ-151 Cream 0.3%
Started20
Completed20
Not completed0

Outcome measures

PrimaryPlasma Concentration of ARQ-151 Cream 0.3%

Plasma levels of circulating roflumilast were determined at 2 points in the study.

Time frame:
Predose on Days 14 and 28
Reported as:
Mean · ng/mL
Plasma Concentration of ARQ-151 Cream 0.3%
ng/mLARQ-151 Cream 0.3%
Day 143.15 ± 3.64
Day 281.68 ± 1.57
PrimaryPlasma Concentration of the Roflumilast Major N-oxide Metabolite

Plasma levels of circulating the roflumilast major N-oxide metabolite were determined at 2 points in the study.

Time frame:
Predose on Days 14 and 28
Reported as:
Mean · ng/mL
Plasma Concentration of the Roflumilast Major N-oxide Metabolite
ng/mLARQ-151 Cream 0.3%
Day 1428.9 ± 41.1
Day 2815.7 ± 15.8
PrimaryNumber of Participants With ≥1 Adverse Event (AE)

The number of participants with adverse events during the treatment period is reported. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Adverse Event (AE)
ParticipantsARQ-151 Cream 0.3%
Number of Participants With ≥1 Adverse Event (AE)4
PrimaryNumber of Participants With Application Site Reactions

The number of subjects experiencing an application site skin reactions by investigator assessment is reported. The investigator assessed for erythema prior to that day's application of investigational product.

Time frame:
Baseline (Day 1), Day 7, and Day 14
Reported as:
Count of participants · Participants
Number of Participants With Application Site Reactions
ParticipantsARQ-151 Cream 0.3%
Day 1: No erythema18
Day 1: Minimal erythema0
Day 1: Definite erythema1
Day 7: No erythema17
Day 7: Minimal erythema3
Day 7: Definite erythema0
Day 14: No erythema19
Day 14: Minimal erythema1
Day 14: Definite erythema0

Adverse events

Collected over Up to 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARQ-151 Cream 0.3%0/20 (0%)0/20 (0%)4/20 (20%)
Most frequent other events
Most frequent other events
EventARQ-151 Cream 0.3%
Candida infectionInfections and infestations1/20
Application site painInjury, poisoning and procedural complications1/20
Back painMusculoskeletal and connective tissue disorders1/20
HeadacheNervous system disorders1/20
Perineal painReproductive system and breast disorders1/20
Nasal congestionRespiratory, thoracic and mediastinal disorders1/20
DermatitisSkin and subcutaneous tissue disorders1/20
Perineal erythemaSkin and subcutaneous tissue disorders1/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)ARQ-151 Cream 0.3%
Mean8.8 ± 1.61
Sex: Female, Male
Sex: Female, Male(Participants)ARQ-151 Cream 0.3%
Female7
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARQ-151 Cream 0.3%
Hispanic or Latino12
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARQ-151 Cream 0.3%
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American10
White9
More than one race0
Unknown or Not Reported0
08

Study locations

17 sites
  • Arcutis Clinical Site 503
    Mountain Brook, Alabama 35223, United States
  • Arcutis Clinical Site 504
    Scottsdale, Arizona 85255, United States
  • Arcutis Clinical Site 509
    Fountain Valley, California 92708, United States
  • Arcutis Site 518
    Los Angeles, California 90017, United States
  • Arcutis Clinical Site 508
    Los Angeles, California 90057, United States
  • Arcutis Clinical Site 511
    Rancho Santa Margarita, California 92688, United States
  • Arcutis Clinical Site 510
    Boca Raton, Florida 33428, United States
  • Arcutis Clinical Site 502
    Coral Gables, Florida 33146, United States
  • Arcutis Clinical Site 513
    Delray Beach, Florida 33484, United States
  • Arcutis Clinical Site 501
    Hialeah, Florida 33016, United States
  • Arcutis Clinical Site 507
    Miami, Florida 33155, United States
  • Arcutis Clinical Site 527
    West Lafayette, Indiana 47906, United States
  • Arcutis Clinical Site 506
    Arlington, Texas 76001, United States
  • Arcutis Clinical Site 519
    Frisco, Texas 75034, United States
  • Arcutis Clinical Site 505
    Houston, Texas 77030, United States
  • Arcutis Clinical Site 521
    Toronto, Ontario MG5-1X8, Canada
  • Arcutis Clinical Site 530
    Santo Domingo, Dominican Republic
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jan 2022, 13 months.

Results were first posted in Dec 2023, 1 year 11 months after primary completion. A results delay was requested in Dec 2022.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 13 months is close to that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 7, 2020
StartActual
Nov 30, 2020
Primary completionActual
Jan 12, 2022
CompletionActual
Jan 12, 2022
Results delay requested
Dec 20, 2022
Results first posted
Dec 15, 2023
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04655313
Responsible party
Sponsor
First posted
Dec 7, 2020
Start date
Nov 30, 2020
Primary completion
Jan 12, 2022
Completion
Jan 12, 2022
Results posted
Dec 15, 2023
Last update
Dec 15, 2023

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion